CN103945869A - 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装 - Google Patents

使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装 Download PDF

Info

Publication number
CN103945869A
CN103945869A CN201280053586.7A CN201280053586A CN103945869A CN 103945869 A CN103945869 A CN 103945869A CN 201280053586 A CN201280053586 A CN 201280053586A CN 103945869 A CN103945869 A CN 103945869A
Authority
CN
China
Prior art keywords
compound
agent
phosphonate
nano
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280053586.7A
Other languages
English (en)
Chinese (zh)
Inventor
T.E.罗杰斯
K.T.全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of CN103945869A publication Critical patent/CN103945869A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201280053586.7A 2011-08-31 2012-08-30 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装 Pending CN103945869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529665P 2011-08-31 2011-08-31
US61/529,665 2011-08-31
PCT/US2012/053211 WO2013033450A2 (en) 2011-08-31 2012-08-30 Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions

Publications (1)

Publication Number Publication Date
CN103945869A true CN103945869A (zh) 2014-07-23

Family

ID=46832627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053586.7A Pending CN103945869A (zh) 2011-08-31 2012-08-30 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装

Country Status (9)

Country Link
US (2) US9216225B2 (https=)
EP (1) EP2750711A2 (https=)
JP (1) JP2014525459A (https=)
KR (1) KR20140064917A (https=)
CN (1) CN103945869A (https=)
BR (1) BR112014004716A2 (https=)
CA (1) CA2845851A1 (https=)
IL (1) IL231216A0 (https=)
WO (1) WO2013033450A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9918190B2 (en) * 2015-02-18 2018-03-13 Cisco Technology, Inc. Augmenting network device management
FR3046728B1 (fr) * 2016-01-19 2020-04-03 Centre National De La Recherche Scientifique Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations.
WO2019009434A1 (ja) * 2017-07-06 2019-01-10 学校法人京都薬科大学 薬物送達用高分子ミセル

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835498A (zh) * 2007-10-05 2010-09-15 古尔比特公司 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的新颖的方法
WO2011097563A1 (en) * 2010-02-08 2011-08-11 Board Of Regents Of The University Of Nebraska Biomineral and metal binding liposomes, their synthesis, and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940961A (en) * 1957-08-09 1960-06-14 Eastman Kodak Co Alkyl 1-acetoxyalkenylphosphonates and polymers thereof
US3006945A (en) * 1960-09-01 1961-10-31 Ethyl Corp Preparation of organic compounds
US3224973A (en) * 1960-09-01 1965-12-21 Ethyl Corp Dialkyl hydroxybenzyl phosphonates as antioxidants
US3367870A (en) * 1963-09-12 1968-02-06 Geigy Chem Corp Method of stabilization with carbonbonded phosphorus derivatives and compositions stabilized thereby
US3681481A (en) 1969-11-12 1972-08-01 Hooker Chemical Corp Catalytic addition of compounds having a p-h bond to acetylene
FR2460958A1 (fr) * 1979-07-09 1981-01-30 Elf Aquitaine Nouveaux composes diphosphoniques, utiles a l'extraction des metaux lourds
DE3065878D1 (en) * 1979-07-09 1984-01-19 Elf Aquitaine Diphosphonic and triphosphonic acid esters, their preparation and applications
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
US4798872A (en) * 1986-04-28 1989-01-17 Ashland Oil, Inc. Alkylene phosphonate acid ester polyols
DE3643684A1 (de) * 1986-12-20 1988-06-30 Hoechst Ag Verfahren zur herstellung von halogenierten phosphono-phosphorsaeureestern und ihre verwendung
DK637888A (da) * 1987-11-24 1989-05-25 Hoffmann La Roche Carboxylsyreestere
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5321153A (en) * 1992-06-15 1994-06-14 Monsanto Company Process for making chiral alpha-amino phosphonates selected novel chiral alpha-amino phosphonates
JPH07140615A (ja) * 1993-11-12 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH07140606A (ja) * 1993-11-19 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4410601A1 (de) * 1994-03-26 1995-09-28 Boehringer Mannheim Gmbh Neue 2.4-Diphosphonoglutarsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1996024599A1 (en) * 1995-02-10 1996-08-15 Akzo Nobel N.V. Synthesis of a hydrocarbylvinyl phosphonic acid hydrocarbyl ester
JP2775426B2 (ja) * 1995-09-14 1998-07-16 工業技術院長 不飽和ホスホン酸エステルの製造方法
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds
JP3007984B1 (ja) * 1999-03-08 2000-02-14 工業技術院長 不飽和ホスホン酸エステルの製造方法
DE60038038T2 (de) * 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
JP3610371B2 (ja) * 2000-03-13 2005-01-12 独立行政法人産業技術総合研究所 （α−及び／又はβ−ホルミルエチル）ホスフィンオキシド化合物、（α−及び／又はβ−ホルミルエチル）ホスホン酸エステル化合物とその製造方法
DE10049074A1 (de) 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
GB0025849D0 (en) * 2000-10-23 2000-12-06 Smithkline Beecham Plc Novel compounds
DE10054218A1 (de) 2000-11-02 2002-05-08 Basf Ag Verfahren zur Herstellung von Alkenylphosphonsäure-Derivaten
EP1506208A4 (en) * 2002-05-11 2006-05-24 Ilex Products Inc 1,1- AND 1,2-BISPHOSPHONATES AS MODULATORS OF APOLIPOPROTEIN E
JP3836395B2 (ja) * 2002-05-17 2006-10-25 独立行政法人科学技術振興機構 アルケニルリン化合物の製造方法
DE102004032781A1 (de) * 2004-01-23 2005-08-11 Mcs Micro Carrier Systems Gmbh Bisphosphonsäurederivate
JP4314366B2 (ja) * 2004-02-18 2009-08-12 独立行政法人産業技術総合研究所 含リンブタジエン化合物の製造方法
WO2006078646A2 (en) 2005-01-18 2006-07-27 Caltagirone Gaetano T A class of supramolecular drug molecules and methods of identification and use thereof
WO2007127488A1 (en) * 2006-04-27 2007-11-08 Shenoy Narmada R Compositions and methods for treating or preventing diseases of body passageways
CN1887890A (zh) * 2006-07-17 2007-01-03 华中师范大学 具有除草活性的α－酰氧基烯基膦酸酯及制备
CN1903862B (zh) * 2006-07-20 2012-10-10 华中师范大学 具有除草活性的取代甲酰氧基烃基膦酸酯类光学活性异构体及制备
WO2009145263A1 (ja) * 2008-05-30 2009-12-03 学校法人東京理科大学 リン酸オセルタミビルの製造方法及び中間体化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835498A (zh) * 2007-10-05 2010-09-15 古尔比特公司 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的新颖的方法
WO2011097563A1 (en) * 2010-02-08 2011-08-11 Board Of Regents Of The University Of Nebraska Biomineral and metal binding liposomes, their synthesis, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABERDEEN ALLEN JR,ET AL.: "Synthesis of functional bisphosphonates via new palladium-catalyzed bis-hydrophosphorylation reactions", 《TETRAHEDRON LETTERS》, vol. 41, 31 December 2000 (2000-12-31), XP002687898 *

Also Published As

Publication number Publication date
US20130066098A1 (en) 2013-03-14
EP2750711A2 (en) 2014-07-09
CA2845851A1 (en) 2013-03-07
US20160060280A1 (en) 2016-03-03
US9216225B2 (en) 2015-12-22
BR112014004716A2 (pt) 2017-03-28
JP2014525459A (ja) 2014-09-29
WO2013033450A2 (en) 2013-03-07
KR20140064917A (ko) 2014-05-28
IL231216A0 (en) 2014-04-30
WO2013033450A3 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
US8889657B2 (en) Nanoparticle PEG modification with H-phosphonates
JP5927194B2 (ja) 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
CN104023793B (zh) 用于治疗癌症的联合脂质体组合物
US8871189B2 (en) MMP-targeted therapeutic and/or diagnostic nanocarriers
CN104039355A (zh) 使用互补性寡核苷酸连接子进行的靶向纳米颗粒的远程组装
JP2017214433A (ja) 修飾されたドセタキセルリポソーム製剤
CN103945869A (zh) 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140723